Columbia: First CRISPR Therapy Approved for Sickle Cell
December 19, 2023
December 19, 2023
NEW YORK, Dec. 19 (TNSres) -- Columbia University issued the following news:
The FDA has approved Casgevy (exa-cel) for treatment of people ages 12 and older with sickle cell disease. Casgevy is the first therapy approved for use in the United States that uses CRISPR gene-editing technology to alter a patient's genes.
"It's tremendously exciting," says hematologist-oncologist Monica Bhatia, MD, associate professor of pediatrics at Columbia University Vagelos . . .
The FDA has approved Casgevy (exa-cel) for treatment of people ages 12 and older with sickle cell disease. Casgevy is the first therapy approved for use in the United States that uses CRISPR gene-editing technology to alter a patient's genes.
"It's tremendously exciting," says hematologist-oncologist Monica Bhatia, MD, associate professor of pediatrics at Columbia University Vagelos . . .